Heather L Gelhorn1, Anne M Skalicky2, Zaneta Balantac2, Sonya Eremenco2, Tricia Cimms3, Katarina Halling4, Patricia J Hollen5, Richard J Gralla6, Martin C Mahoney7, Chris Sexton2. 1. Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA. heather.gelhorn@evidera.com. 2. Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA. 3. AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA. 4. AstraZeneca, Molndal, SE-431 83, Gothenburg, Sweden. 5. University of Virginia, Charlottesville, VA, 22903-3387, USA. 6. Albert Einstein College of Medicine, Bronx, NY, 10461, USA. 7. Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Abstract
PURPOSE: Obtaining qualitative data directly from the patient perspective enhances the content validity of patient-reported outcome (PRO) instruments. The objective of this qualitative study was to evaluate the content validity of the Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso) and its usability on an electronic device. METHODS: A cross-sectional methodological study, using a qualitative approach, was conducted among patients recruited from four clinical sites. The primary target population included patients with pleural mesothelioma; data were also collected from patients with peritoneal mesothelioma on an exploratory basis. Semi-structured interviews were conducted consisting of concept elicitation, cognitive interviewing, and evaluation of electronic patient-reported outcome (ePRO) usability. RESULTS: Participants (n = 21) were interviewed in person (n = 9) or by telephone (n = 12); 71% were male with a mean age of 69 years (SD = 14). The most common signs and symptoms experienced by participants with pleural mesothelioma (n = 18) were shortness of breath, fluid build-up, pain, fatigue, coughing, and appetite loss. The most commonly described symptoms for those with peritoneal mesothelioma (n = 4) were bloating, changes in appetite, fatigue, fluid build-up, shortness of breath, and pain. Participants with pleural mesothelioma commonly described symptoms assessed by the LCSS-Meso in language consistent with the questionnaire and a majority understood and easily completed each of the items. The ePRO version was easy to use, and there was no evidence that the electronic formatting changed the way participants responded to the questions. CONCLUSIONS: Results support the content validity of the LCSS-Meso and the usability of the electronic format for use in assessing symptoms among patients with pleural mesothelioma.
PURPOSE: Obtaining qualitative data directly from the patient perspective enhances the content validity of patient-reported outcome (PRO) instruments. The objective of this qualitative study was to evaluate the content validity of the Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso) and its usability on an electronic device. METHODS: A cross-sectional methodological study, using a qualitative approach, was conducted among patients recruited from four clinical sites. The primary target population included patients with pleural mesothelioma; data were also collected from patients with peritoneal mesothelioma on an exploratory basis. Semi-structured interviews were conducted consisting of concept elicitation, cognitive interviewing, and evaluation of electronic patient-reported outcome (ePRO) usability. RESULTS:Participants (n = 21) were interviewed in person (n = 9) or by telephone (n = 12); 71% were male with a mean age of 69 years (SD = 14). The most common signs and symptoms experienced by participants with pleural mesothelioma (n = 18) were shortness of breath, fluid build-up, pain, fatigue, coughing, and appetite loss. The most commonly described symptoms for those with peritoneal mesothelioma (n = 4) were bloating, changes in appetite, fatigue, fluid build-up, shortness of breath, and pain. Participants with pleural mesothelioma commonly described symptoms assessed by the LCSS-Meso in language consistent with the questionnaire and a majority understood and easily completed each of the items. The ePRO version was easy to use, and there was no evidence that the electronic formatting changed the way participants responded to the questions. CONCLUSIONS: Results support the content validity of the LCSS-Meso and the usability of the electronic format for use in assessing symptoms among patients with pleural mesothelioma.
Entities:
Keywords:
HRQL; Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso); Patient-reported outcome; Symptoms
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-13 Impact factor: 5.725
Authors: Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven Journal: Support Care Cancer Date: 2005-07-06 Impact factor: 3.603
Authors: Patricia J Hollen; Richard J Gralla; John A Stewart; Jacinta M Meharchand; Rafal Wierzbicki; Natasha Leighl Journal: Support Care Cancer Date: 2012-06-10 Impact factor: 3.603
Authors: Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven Journal: Cancer Date: 2004-08-01 Impact factor: 6.860
Authors: Margaret Rothman; Laurie Burke; Pennifer Erickson; Nancy Kline Leidy; Donald L Patrick; Charles D Petrie Journal: Value Health Date: 2009-09-25 Impact factor: 5.725
Authors: Jolie N Haun; Amy C Alman; Christine Melillo; Maisha Standifer; Julie McMahon-Grenz; Marlena Shin; W A Lapcevic; Nitin Patel; A Rani Elwy Journal: JMIR Med Inform Date: 2020-06-26
Authors: Tito R Mendoza; Loretta A Williams; Karen N Keating; Jonathan Siegel; Cem Elbi; Anna K Nowak; Raffit Hassan; Brian Cuffel; Charles S Cleeland Journal: J Patient Rep Outcomes Date: 2019-06-17